152, 722â€"723) recently reported two cases of neuro leptic-induced extrapyramidal side-effects (EPS) (muscle rigidity and drooling)which weresuccessfully treated with oral calcium. Both patients had EPS which persisted in spite of anticholinergic or antihis taminic agents (benztropine, procyclidine, or diphenhydramine).
We have completed three studies of the effects of the calcium-channel antagonists (CCAs) verapamil, nifedipine, and diltiazem on tardive dyskinesia, dur ing which EPS were also rated (Reiter et al, 1989;  Adler ci a!, 1988; Duncan ci a!, in preparation).
Based on the report of Drs Fernando & Machanda, we assessed whether there was any increase in EPS after administration of the CCAs.
Methods were similar for all three studies. EPS were quantified by the Hillside/LU modification of the original Simpson/Angus EPS Scale (Simpson & Angus, 1970) . EPS ratings were performed on alter nate days over a 5â€"15 day period by a rater who did not know when treatment with CCAs was to begin.
Each patient was rated by the same evaluator throughout the trial. Multiple ratings were made in order to blind the rater. All ratings were discarded except for those which were obtained immediately before treatment and on the last day of treatment.
Neuroleptics and all other medications were held constant for at least four days before, and through out the course of treatment with CCA. Patients were excluded if they had any contraindications to CCAs (e.g. hypotension, cardiac conduction delays or block) or cardiovascular illness requiring medi cation.
CCAs were prescribed by physicians who did not rate the patients. The initial doses of CCAs were: verapamil, 160 mg/day; diltiazem, 120 mg/day; or nifedipine, 30mg/day. For those patients who did not develop hypotension or bradycardia the dose was increased to: verapamil, 320 mg/day; diltiazem, 240 mg/day; or nifedipine, 60mg/day. No significant effects were observed on EPS after any of the CCAs (all 1<1). EPS scores were unchanged from a mean of 3.1 Â± 2.5 at baseline to a mean of 2.8Â±2.0 after verapamil (t(8)=0.71, NS). EPS was also unchanged after diltiazem (mean at baseline = 3.5 Â±3.3, mean after diltiazem = 3.2 Â± 2.8; t(l1)= 0.65, NS) and after nifedipine (mean at base line = 2.1 Â± 2.1, mean after diltiazem = 2.0 Â±1.6, NS).
No clinically apparent changes in EPS were observed in any of the individual patients.
Our findings of an absence of effect of the CCAs verapamil, diltiazem, or nifedipine on EPS in no way contradicts the reported improvement in EPS after administration of calcium. Calcium may affect EPS via mechanisms different from those which affect cel lular gating or intracellular calcium concentrations. Nonetheless, Drs Fernando & Machanda's findings might lead one to predict that CCA treatment would increase the mild EPS that our patients showed at baseline; this was not observed. had been widowedthree yearsearlier, complainedbitterly of repeated, uncontrolled orgasms. These occurred up to 30 times per day without any sort of sexual contact. Her social functioning was severely impaired and she stopped practis ingher regular religious rituals and visiting the holy shrines.
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